Remarkable Clinical Response of ALK-Rearranged/TP53-Mutant Lung Adenocarcinoma with Liver Metastasis to Atezolizumab-Bevacizumab-Carboplatin-Paclitaxel After ALK Inhibitors: A Case Report

Anaplastic lymphoma kinase-positive (ALK-positive) lung adenocarcinoma with multiple liver metastases accounts for a relatively small number of cases of non-small cell lung cancer. Several ALK-tyrosine kinase inhibitors (ALK-TKIs) are available for the treatment of lung cancer. However, there is lim...

Descripción completa

Detalles Bibliográficos
Autores principales: Iso, Hirokazu, Miyanaga, Akihiko, Kadoma, Naohiro, Shinbu, Kaoruko, Tozuka, Takehiro, Murata, Akari, Nishima, Shunichi, Sato, Yozo, Nakamichi, Shinji, Matsumoto, Masaru, Noro, Rintaro, Terasaki, Yasuhiro, Kubota, Kaoru, Seike, Masahiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296560/
https://www.ncbi.nlm.nih.gov/pubmed/37384219
http://dx.doi.org/10.2147/OTT.S404035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296560/
https://www.ncbi.nlm.nih.gov/pubmed/37384219
http://dx.doi.org/10.2147/OTT.S404035

Ejemplares similares